Skip to content

Research at St Andrews

6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: design, synthesis and in vitro evaluation

Research output: Research - peer-reviewArticle

DOI

Open Access permissions

Open

Author(s)

Ondrej Benek, Lukas Hroch, Laura Aitken, Rafael Dolezal, Patrick Guest, Marketa Benkova, Ondrej Soukup, Karel Musil, Rebecca Hughes, Kamil Kuca, Terry K. Smith, Frank Gunn-Moore, Kamil Musilek

School/Research organisations

Abstract

Background: The mitochondrial enzyme amyloid beta-binding alcohol dehydrogenase (ABAD) also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) has been connected with the pathogenesis of Alzheimer’s disease (AD). ABAD/ 17β-HSD10 is a binding site for the amyloid-beta peptide (Aβ) inside the mitochondrial matrix where it exacerbates Aβ toxicity. Interaction between these two proteins triggers a series of events leading to mitochondrial dysfunction as seen in AD.
Methods: As ABAD’s enzymatic activity is required for mediating Aβ toxicity, its inhibition presents a promising strategy for AD treatment. In this study, a series of new benzothiazolylurea analogues have been prepared and evaluated in vitro for their potency to inhibit ABAD/ 17β-HSD10 enzymatic activity. The most potent compounds have also been tested for their cytotoxic properties and their ability to permeate through blood-brain barrier has been predicted. To explain the structure-activity relationship QSAR and pharmacophore studies have been performed.
Results and Conclusions: Compound 12 was identified being the most promising hit compound with good inhibitory activity (IC50 = 3.06 ± 0.40µM) and acceptable cytotoxicity profile comparable to the parent compound of frentizole. The satisfactory physical-chemical properties suggesting its capability to permeate through BBB make compound 12 a novel lead structure for further development and biological assessment.
Close

Details

Original languageEnglish
Pages (from-to)345-358
Number of pages14
JournalMedicinal Chemistry
Volume13
Issue number4
Early online date9 Jan 2017
DOIs
StatePublished - Jun 2017

    Research areas

  • Alzheimer's disease, Amyloid-beta binding alcohol dehydrogenase (ABAD), 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), Chemical synthesis, Enzyme inhibition, Frentizole, QSAR, Pharmacophore modelling

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. In vitro assay development and HTS of small molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer’s Disease

    Aitken, L., Baillie, G., Pannifer, A., Morrison, A., Jones, P. S., Smith, T. K., McElroy, S. P. & Gunn-Moore, F. J. Jul 2017 In : SLAS Discovery. 22, 6, p. 676-685 11 p.

    Research output: Research - peer-reviewArticle

  2. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment

    Hroch, L., Guest, P., Benek, O., Soukup, O., Janockova, J., Dolezal, R., Kuca, K., Aitken, L., Smith, T. K., Gunn-Moore, F., Zala, D., Ramsay, R. R. & Musilek, K. 1 Feb 2017 In : Bioorganic & Medicinal Chemistry. 25, 3, p. 1143-1152 10 p.

    Research output: Research - peer-reviewArticle

  3. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer’s disease treatment

    Hroch, L., Benek, O., Guest, P., Aitken, L., Soukup, O., Janockova, J., Musil, K., Dohnal, V., Dolezal, R., Kuca, K., Smith, T. K., Gunn-Moore, F. J. & Musilek, K. 1 Aug 2016 In : Bioorganic and Medicinal Chemistry Letters. 26, 15, p. 3675-3678 4 p.

    Research output: Research - peer-reviewLetter

  4. Morphology-specific inhibition of β-amyloid aggregates by 17β-hydroxysteroid dehydrogenase type 10

    Aitken, L., Quinn, S. D., Perez-Gonzalez, D. C., Samuel, I. D. W., Penedo-Esteiro, J. C. & Gunn-Moore, F. J. 2 Jun 2016 In : ChemBioChem. 17, 11, p. 1029-1037

    Research output: Research - peer-reviewArticle

  5. Benzothiazoles - Scaffold of interest for CNS targeted drugs

    Hroch, L., Aitken, L., Benek, O., Dolezal, M., Kuca, K., Gunn-Moore, F. J. & Musilek, K. 2015 In : Current Medicinal Chemistry. 22, 6, p. 730-747 18 p.

    Research output: Research - peer-reviewArticle

ID: 248866050